Lipiodol retention pattern predicts transarterial chemoembolization therapeutic effect in hepatocellular carcinoma

Main Article Content

Margaretha Vianny
Gunawan Santosa
Eddy Soedijanto

Abstract

BACKGROUND Hepatocellular carcinoma (HCC) incidence is increasing in Asia and Africa. Locoregional minimally invasive transarterial chemoembolization (TACE) is the palliative therapy of choice, improving survival rate. Adequate lipiodol dose calculation in TACE is necessary to produce good therapeutic effect. Lipiodol retention pattern can predict TACE therapeutic effect. This study aimed to determine correlation of lipiodol volume/tumor volume (L/V) ratio and lipiodol volume/tumor diameter (L/D) ratio with lipiodol retention pattern in post-TACE CT-scans of HCC patients. METHODS This cohort prospective study was done from November 2013 to March 2014 on eighteen HCC patients with post-TACE therapy in Dr.Kariadi Hospital, Semarang, fullfilling inclusion and exclusion criteria. Lipiodol retention pattern was observed on 28 days post-TACE and classified as type I (lipiodol accumulation in tumor and surrounding area), type II (homogenous accumulation in tumor only), and type III (partial accumulation). The Spearman correlation test was used to determine any relationships between the various variables studied. RESULTS Spearman correlation test showed that lipiodol volume had significant moderate correlation with lipiodol retention pattern (r=-0.684; p=0.002). Both L/V and L/D ratios had moderately significant correlation with lipiodol retention pattern (r=0.511; p=0.030; and r=0.518; p=0.028, respectively). CONCLUSION Correlations of L/V ratio L/D ratio with lipiodol retention pattern were both moderately significant. Lipiodol dose calculation based on L/V ratio is suggested considering the irregular three-dimensional form of the tumor, making volumetric measurement more appropriate.

Article Details

How to Cite
Vianny, M., Santosa, G., & Soedijanto, E. (2015). Lipiodol retention pattern predicts transarterial chemoembolization therapeutic effect in hepatocellular carcinoma. Universa Medicina, 34(1), 52–60. https://doi.org/10.18051/UnivMed.2015.v34.52-60
Section
Review Article

References

Altekruse S, McGlynn K, Reichman M.

Hepatocellular carcinoma incidence, mortality,

and survival trends in the United States from

to 2005. J Clin Oncol 2009;27:1485-91.

Siegel R, Naishadham D, Jemal A. Cancer

statistics 2013. CA Cancer J Clin 2013;63:11-

Venook AP, Papandreou C, Furuse J, et al. The

incidence and epidemiology of hepatocellular

carcinoma: a global and regional perspective.

Oncologist 2010;15 Suppl 4:S5-13.

Gomaa AI, Khan SA, Toledano MB, et al.

Hepatocellular carcinoma: epidemiology, risk

factors and pathogenesis. World J Gastroenterol

;21;14:4300-8.

Parkin DM, Bray F, Ferlay J, et al. Global cancer

statistics, 2002. CA Cancer J Clin 2005;55:74-

Ferlay J, Shin HR, Bray F, et al. Estimates of

worldwide burden of cancer in 2008:

GLOBOCAN 2008. Int J Cancer 2010;127:

-917.

Gani RA. Faktor risiko dan mekanisme

karsinogenesis hepatoma. Semarang:

Gastroenterohepatology Update II Clinical

application in Gastroenterohepatology;2012.

Marrero J. Current treatment approaches in

HCC. Clin Adv Hematol Oncol 2013;11 Suppl

:S15-8.

Adam A, Mueller PR. Interventional radiological

treatment of liver tumors. New York: Cambridge

University Press;2009.

Kawaguchi T, Ohkawa K, Imanaka K, et al.

Lipiodol accumulation and transarterial chemo

embolization efficacy for HCC patients.

Hepatogastroenterol 2012;59:219-23.

Lo CM, Ngan H, Tso WK, et al. Randomized

controlled trial of transarterial lipiodol

chemoembolization for unresectable

hepatocellular carcinoma. Hepatol 2002;35:

-71.

Kasai K, Ushio A, Kasai Y, et al. Therapeutic

efficacy of transarterial chemo-embolization with

a fine-powder formulation of cisplatin for

hepatocellular carcinoma. World J Gastroenterol

;19:2242-8.

Takayasu K, Arii S, Ikai I, et al. Prospective

cohort study of transarterial chemoembolization

for unresectable hepatocellular carcinoma in

patients. Gastroenterol 2006;131:461-9.

Cruite I, Tang A, Sirlin CB. Imaging-based

diagnostic systems for hepatocellular carcinoma.

Am J Roentgenol 2013;201:41-55.

Bialecki ES, Bisceglie AM. Diagnosis of

hepatocellular carcinoma. HPB 2005;7:26-34.

Pentecost M. Interventional therapies for hepatic

malignancy. In: Baum S, Pentecost M, editors.

Abram’s angiography interventional radiology.

Philadelphia: Lippinott Wiliams & Wikins;2006.

p.516-24.

Shin WS. The current practice of transarterial

chemoembolization for the treatment of

hepatocellular carcinoma. Korean J Radiol 2009;

:425-34.

Cheng HY, Xu AM, Chen D, et al. Adjustment

of lipiodol dose according to tumor blood supply

during the transcatheter arterial

chemoembolization for large hepatic carcinoma

by multidetector helical CT. Chinese J Oncol

;25:186-9.

Lim HS, Jeong YY, Kang HK, et al. Imaging

features of hepatocellular carcinoma after

transcatheter arterial chemoembolization and

radiofrequency ablation. Am J Roentgenol 2006;

:341-9.

Matsuo N, Uchida H, Sakaguchi H, et al. Optimal

lipiodol volume in transcatheter arterial

chemoembolotherapy for hepatocellular

carcinoma: study based on lipiodol accumulation

patterns and histopathologic findings. Semin

Oncol 1997;24 Suppl 6:S67-70.

Llovlet JM, Ducreux M, Lencioni R, et al.

EASL—EORTC clinical practice guidelines:

management of hepatocellular carcinoma. J

Hepatol 2012;56: 908-43.

Talwalkar JA, Gores GJ. Diagnosis and staging

of hepatocellular carcinoma. Gastroenterol

;127 Suppl 1:S126-32.

Omata M, Lesmana LA, Tateishi R, et al. Asian

Pacific Association for the Study of the Liver

consensus recommendations on hepatocellular

carcinoma. Hepatol Int 2010;4:439-74.

Jelic S, Sotiropoulos GC. Hepatocellular

carcinoma: ESMO clinical practice guidelines

for diagnosis, treatment and follow-up. Ann

Oncol 2010;21 Suppl 5:S59-64.

Zhang JW, Feng XY, Liu HQ, et al. CT volume

measurement for prognostic evaluation of

unresectable hepatocellular carcinoma after

TACE. World J Gastroenterol 2010;16:2038-45.

Prasad SR, Jhaveri KS, Saini S, et al. CT tumor

measurement for therapeutic response

assessment: comparison of unidimensional,

bidimensional, and volumetric techniques initial

observations. Radiol 2002;225:416-9.

Guan YS, Hu Y, Liu Y. Multidetector-row

computed tomography in the management of

hepatocellular carcinoma with transcatheter

arterial chemoembolization. J Gastroenterol

Hepatol 2006;21:941-6.